Author

Emma Armstrong

Observed name: E. Armstrong

Institution: The Royal Melbourne Hospital

Observed institutions: The Royal Melbourne Hospital, Memorial Sloan Kettering Cancer Center, Wihuri Research Institute

ORCID: 0000-0001-8748-691X

Observed ORCID: 0000-0001-8748-691X

OpenAlex ID: A5023916655

VEGF-B Promotes Endocardium-Derived Coronary Vessel Development and Cardiac Regeneration

2020 · Markus Räsänen, Ibrahim Sultan, et al. · Circulation · 113

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study

2022 · F. Dimitriou, K. Namikawa, et al. · Annals of Oncology · 70

Clinical and genomic correlates of imatinib response in melanomas with KIT alterations

2022 · Seungyeon Jung, Emma Armstrong, et al. · British Journal of Cancer · 30

Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma

2022 · Lukas Kraehenbuehl, Aliya Holland, et al. · Cancers · 21

Impact of enteral tube feeding for individuals with disorders of the gut brain interaction

2023 · R. Gallo, E. Armstrong, et al. · Clinical Nutrition ESPEN · 3

Underutilisation of gastric emptying studies and underrecognition of gastroparesis in people with diabetes treated in a hospital setting

2023 · Joanna Y. Gong, Dinesh Sivaratnam, et al. · Internal Medicine Journal · 2

1049P Clinical models to predict response in mucosal melanoma (MM) patients (pts) treated with anti-PD-1 (PD1) or combined with ipilimumab (PD1+IPI)

2021 · F. Dimitriou, K. Namikawa, et al. · Annals of Oncology · 2

Abstract 1514: Examining the impact of chromosomal instability on mucosal melanoma tumor infiltrate and responses to PD-1 based therapy

2022 · Emma Armstrong, Lee Gottesdiener, et al. · Cancer Research

Works count: 8

Citation count: 241

H-index: 4

I10-index: 4